Effectiveness of Repeat-dose CRD-4730 in Participants with CPVT

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2024
This is a Phase 2, multicenter, double-blind, sponsor blinded, placebo-controlled, repeat-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 to participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). The study will have 3 cohorts in which participants with CPVT will participate in a 3-period, randomized 3-sequence study. Each participant will receive 2 different doses of CRD-4730 and 1 dose of matching placebo.
Epistemonikos ID: 2a0393db7c063b94fbbdfa6975b7d3b374ab89b8
First added on: Apr 17, 2025